

09/22/98
JCS98 U.S. PRO

Patent
Attorney's Docket No. 007198-353

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY PATENT
APPLICATION TRANSMITTAL LETTER

JCS11 U.S. PRO
09/15/98
09/22/98

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed for filing is the utility patent application of Kwok On Lai and Nancy Yuk-Yu Ip for CLONING OF A NOVEL NEUROTROPHIN NT-7 FROM CARP.

Also enclosed are:

- ☐ _____ sheet(s) of ☐ formal ☐ informal drawing(s);
- ☐ a claim for foreign priority under 35 U.S.C. §§ 119 and/or 365 is ☐ hereby made to _____ filed in _____ on _____;
☐ in the declaration;
- ☐ a certified copy of the priority document;
- ☐ a Constructive Petition for Extensions of Time;
- ☒ 1 statement(s) claiming small entity status;
- ☒ an Assignment document;
- ☐ an Information Disclosure Statement; and
- ☒ Other: Preliminary Amendment

The declaration of the inventor(s) ☒ also is enclosed ☐ will follow.

- ☐ Please amend the specification by inserting before the first line the sentence --This application claims priority under 35 U.S.C. §§119 and/or 365 to _____ filed in _____; the entire content of which is hereby incorporated by reference.--

The filing fee has been calculated as follows [X] and in accordance with the enclosed preliminary amendment:

CLAIMS					
	NO. OF CLAIMS		EXTRA CLAIMS	RATE	FEE
Basic Application Fee					\$790.00
Total Claims	5	MINUS 20 =	-0-	x \$22.00	-0-
Independent Claims	5	MINUS 3 =	2	x \$82.00	164.00
If multiple dependent claims are presented, add \$270.00					-0-
Total Application Fee					954.00
If verified Statement claiming small entity status is enclosed, subtract 50% of Total Application Fee					477.00
Add Assignment Recording Fee of \$40.00 if Assignment document is enclosed					40.00
TOTAL APPLICATION FEE DUE					517.00

[X] A check in the amount of \$ 517.00 is enclosed for the fee due.

[] Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.

Please address all correspondence concerning the present application to:

James A. LaBarre
Burns, Doane, Swecker & Mathis, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in triplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: September 22, 1998

By: 

James A. LaBarre
Registration No. 28,632

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Applicant or Patentee: The Hong Kong University of Science & Technology
Application or Patent No.: _____
Filed or Issued: _____
For: Cloning of a Novel Neurotrophin NT-7 from Carp.

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 C.F.R. §§ 1.9(f) AND 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION The Hong Kong University of Science & Technology
ADDRESS OF ORGANIZATION Clear Water Bay, Kowloon, Hong Kong

TYPE OF ORGANIZATION

- ☒ [X] University or other institution of higher education
☐ [] Tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3))
☐ [] Nonprofit scientific or educational under statute of state of The United States of America
(Name of state _____)
(Citation of statute _____)
☐ [] Would qualify as tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3)) if located in The United States of America
☐ [] Would qualify as nonprofit scientific or educational under statute of The United States of America if located in The United States of America
(Name of state _____)
(Citation of statute _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees under Sections 41(a) and 41(b) of Title 35, United States Code, with regard to the invention entitled Cloning of a Novel Neurotrophin NT-7 from Carp. by inventor(s) Kwok On Lai and Nancy Yuk-Yu Ip described in _____

- ☐ [] the specification filed herewith
☐ [] Application No. _____, filed _____
☐ [] Patent No. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern, or organization having rights to the invention is listed below,* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an individual inventor under 37 C.F.R. § 1.9(c), or by any concern that would not qualify as either a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27.)

FULL NAME _____

ADDRESS _____
[] individual [] small business concern [] nonprofit organization

FULL NAME _____

ADDRESS _____
[] individual [] small business concern [] nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee and any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b).)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dr. Keith WHITE-HUNT

TITLE IN ORGANIZATION Director of Technology Transfer Centre

ADDRESS OF PERSON SIGNING Hong Kong University of Science and Technology,
Clear Water Bay, Kowloon

SIGNATURE  DATE 1 June 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Kwok On Lai et al) Group Art Unit: Unassigned
)
Application No.: Unassigned) Examiner: Unassigned
)
Filed: Herewith)
)
For: CLONING OF A NOVEL)
NEUROTROPHIN NT-7)
FROM CARP)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, kindly amend the above-identified application as follows:

IN THE CLAIMS:

Claim 2, line 1, at the beginning of the sentence, insert --A nucleic acid sequence
comprising:--

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

James A. LaBarre
Registration No. 28,632

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date:

09157984,092298

FIELD OF INVENTION

The invention relates to a novel neurotrophin called NT-7. NT-7 possesses structural characteristics of the family of neuroactive proteins called neurotrophins. NT-7 has been found to support the survival and neurile outgrowth of embryonic chick dorsal root ganglion neurons and has been found to activate the receptor tyrosine kinase, Trks.

BACKGROUND

A new stage of development begins with the formation of synaptic contacts between growing axons and their synaptic partners. Once these synaptic contacts are made, the neurons are partly dependent on the presence of their partners for continued survival and differentiation. In the absence of the synaptic targets the axons and dendrites of developing neurons atrophy and the nerve cells may die. The long-term dependency between neurons and their target is called trophic interaction. Neurotrophic factors are signalling molecules provided to neurons by trophic interaction. Neurotrophic factors originate from target tissues and regulate neuronal survival and subsequent growth and differentiation. The two major functions of neurotrophic signalling are the survival of a subset of neurons from a considerably larger population, and the formation of appropriate numbers of connections. The current neurotrophic hypothesis makes a number of assumptions about neurons and their targets. First, neurons depend on the availability of a minimum concentration of trophic factor for survival and subsequently for the persistence of their target connections. Secondly, target tissues synthesise and make available to

00157984-062268
002268-18675160

developing neurons appropriate trophic factors. Third, targets produce trophic factors in limited amounts. Consequently the survival of developing neurons (and later, the persistence of neuronal connections) depends upon neuronal competition for available neurotrophic factor. It is now known that neurotrophins are a family of related trophic proteins. This family consists of four members in mammals that share high homology to each other (about 50% amino acid identity).

The first identified neurotrophic factor, nerve growth factor (NGF) mediates cell survival among two specific neuronal populations in birds and mammals (sympathetic and a sub-population of sensory ganglion cells). Research has shown the death of the relevant neurons in the absence of NGF, survival of a surplus of neurons in the presence of elevated levels of factor; the presence and production of NGF in neuronal targets; and the existence of receptors for NGF in innervating nerve terminals. These observations now define the criteria that must be satisfied to conclude that a factor is a neurotrophin.

Other known members of the neurotrophin family include brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and NT-4/5. Another neurotrophin, NT-6 has been discovered from the platfish *Xiphophorus maculatus* and *Xiphophorus Lellen* (Gotz et al, 1994).

Neurotrophins bind to two classes of receptors: the p75 receptor binds to neurotrophic with low affinity whilst higher affinity binding is observed with a family of receptor tyrosine kinases called Trks. This family of receptors currently contains three proteins designated TrkA, TrkB and TrkC.

The expression of a particular Trk receptor confers on the neuron the capacity to respond to the corresponding neurotrophin. Also, since neurotrophins and Trk receptors are expressed only in certain cell types in the nervous system, the binding between the neurotrophic factor and receptor accounts for the specificity of neurotrophic interactions.

Binding of neurotrophic factors to their specific receptors result in the phosphorylation of the Trk receptor.

NGF specifically activates TrkA, BDNF and NT-4/5 interact with TrkB whilst NT-3 preferentially activates TrkC.

All the neurotrophins are basic proteins of about 120 amino acids being processed from larger precursors. There are some structural features common to all members of the neurotrophin family. These include encoding of the whole precursor protein in a single exon, the basic amino acids at the end of the pre-pro region that are important in proteolytic cleavage during processing of the precursor molecule, and the presence of six cysteine residues that are thought to maintain three-dimensional conformation of the molecule by disulfide bond formation. Moreover, there are conserved regions, mainly around the cysteine residues, that contain similar amino acid sequences in all neurotrophins. Taken together, these structural features define useful criteria in the identification of novel neurotrophins.

Alignment of amino acid sequence with other neurotrophins suggests that NT6 is structurally more related to NGF. However, NT-6 contains an additional

feature not shared by all other known neurotrophins: an insertion of 22 amino acids between the second and third cysteine residues of the mature molecule which contains the heparin-binding domain. Although NT-6 is able to support the survival of chick sympathetic and dorsal root ganglion neurons, its potency is much lower than that of mouse NGF, probably reflecting low conservation of the molecule during evolution.

It is an object of the invention to provide a novel neurotrophin.

SUMMARY OF INVENTION

The invention provides an essentially purified neurotrophin, NT-7 having neurotrophic activity and an amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7.

The invention also provides a nucleic acid sequence:

AAGGCCAACGACTTCTTGCATCGCGGCGAGTACTCTGTGTGTGACAGCGAAGA
GCACTGGGTGGCAACCTGACCCAAGCCACAGACTTACGGGGCAATGAAGTCA
CGGTGCTGCCACATGTTTCGCATCAACAACGTGGTGAAGAAGCAGATGTTCTAC
GAGACCACGTGCCGTGTGTGGAAGCCCATCGGGGCCCCCAAGCCGGGTCAAG
GAGTCAGCGGCGTTAAAGCAGGAACCTCTAGCTGTCTGTGGATCGACAACGAG
CACTGGAACCTTATTGCACCAACGTGCACACCTTTGTGCGGGCGTTAACGTCC
TACAAAAACCAGATTGCCTGGAGGTTATCCGAATCAACGCCGCTTGCCTGTG
CGTCCTCAGCCGCAACTCATGGAGGCAT

said nucleic sequence including degenerate versions of the sequence and
including nucleic acid sequences that hybridise under stringent conditions to said
nucleic acid sequences and encode NT-7.

The invention also provides a composition comprising an essentially purified
neurotrophin, NT-7 having neurotrophic activity and an amino acid sequence as
follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7.

The invention also provides the use of an essentially purified neurotrophin NT-7
having neurotrophic activity and an amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
 Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
 Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
 Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
 Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
 Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
 Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7 in the
 treatment of acute and/or chronic neuronal injury or degenerative states for a
 specific subclass of neurons.

The invention also provides the use of an essentially purified neurotrophin NT-7
 having neurotrophic activity and an amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
 Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
 Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
 Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
 Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
 Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
 Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7 in the
 identification of additional members of the neurotrophin family.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described, by way of example only and with reference to the following embodiments:

Figure 1 shows the nucleotide and deduced amino acid sequence of carp NGF and NT-7.

- (A) The basic motif RVRR (double underlined) was the putative proteolytic cleavage site, followed by an open reading frame of 133 amino acids that constituted the mature protein (starting with the lysine residue as indicated by the arrowhead). Exact oligonucleotides at two conserved regions of *Xiphophorus* NT-6 (corresponded to nucleotide 51 to 68 and 374 to 390 of NT-7) were used to perform the initial PCR from carp genomic DNA that generated the partial sequence of NT-7. The conserved cysteine residues in the mature region, as well as the conserved sequence nearby, were underlined. There is a characteristic insertion of 15 amino acids between the second and third cysteine residues (bolded). Note the entire pre-pro region that contained the putative ATG start codon 141, 195, 208, and 283, with changes at the Ile⁷⁰ and Glu⁹⁵ to Val and Lys, respectively.
- (B) Partial nucleotide sequence and the deduced amino acid sequence of carp NGF. A 177-bp fragment corresponded to the partial sequence between

the second and the fifth conserved cysteine residues of carp NGF. The underlined sequence represented positions of the degenerate primers.

Figure 2 shows the alignment of carp NGF and NT-7 with other neurotrophins.

- (A) Alignment of NGF and NT-7 with other known neurotrophins from lower vertebrates (Xipma represented *Xiphophorus maculatus*; Xen represented *Xenopus laevis*). Amino acids identical to that of NT-7 were represented by dots, while gaps were indicated by dash. Conserved regions among all the neurotrophins were underlined. The 15-amino-acid insertion (double underlined) was characteristic to this novel neurotrophin. The mature region of NT-7 shared 66% amino acid identity to Xipma NGF and NT-6 (without taking into account the insertion).
- (B) Alignment of carp NGF and NT-7 with NGF from various animals. Only partial sequence of salmon NGF had been reported. The amino acid residues that were conserved in all known NGF but different in NT-7 were bolded.

Figure 3 shows a Southern blot analysis of *Hind*III-cut *Xiphophorus* genomic DNA. The digested DNA was hybridised with cDNA of *Xiphophorus* NGF, NT-6, or carp NT-7 under low stringency. Numbers on the left indicated the sizes of the *Hind*III-digested lambda marker DNA (in kilobases). Distinct bands of ~8 and ~3, and ~2 kb hybridised with *Xiphophorus* NGF, NT-6, and carp NT-7 respectively.

Figure 4 shows a Northern blot analysis of the spatial expression of NT-7 and NGF in adult fish.

- (A) Spatial expression of NT-7 in adult carp was examined. A single transcript of ~1.1 kb was detected in skin and heart. Weak expression was also found in brain and intestine.
- (B) Spatial expression of NGF in *Xiphophorus*. A transcript of ~3.6 kb was detected predominantly in eye and gill, while expression in skin was much weaker, in both A and B, the corresponding ethidium bromide-stained gel indicated similar amount of RNA loaded in each lane.

Figure 5 is an RT-PCT showing the presence of the 15 amino-acid insertion in the transcript of NT-7.

A fragment of 304 bp (indicated by upper arrowhead), which corresponded to the presence of the insertion, was produced after amplification from brain, heart, intestine, and skin cDNA by a pair of primers flanking the insertion (nucleotide 69 to 85 and 358 to 373 in Figure 1). The RNA was replaced by DEPC-H₂O in the no-RNA control, while the same concentration of RNA but without reverse transcriptase was used in the no-RT control. NT-7 and NT-7(D15) represented PCR products amplified by the same primers from the expression plasmids NT-7 and NT-7(D15) which lacked the 15-amino-acid insertion (indicated by lower arrowhead), respectively. These served as the size standards to demonstrate that the insertion was present in the transcripts from the various tissues.

Figure 6 shows the biological activities of the various fish neurotrophins.

Photomicrographs showing E8 chick DRG after 1 day treatment with COS cell supernatant from mock-transfected cells (A), or from cells transfected with *Xiphophorus* NGF (B), NT-6 (C), NT-6(D22), (D), NT-7 (E), and NT-7(D15) (F).

At least five DRGs were placed in each 35-mm dish coated with 1 ug/ml poly-D-lysine and treated with 1:5 diluted COS cell supernatant. The DRG were fixed and stained by anti-neurofilament 160-KDa antibody. Extensive neurite outgrowth was observed from DRG treated with *Xiphophorus* NGF, NT-7, or NT-7(D15) but not NT-6 and NT-6(D22). After pre-pro exchange with *Xiphophorus* NGF, NT-6 and NT-6(D22) were still unable to induce neurite outgrowth of DRG explant (data not shown). Magnification x60.

Figure 7 shows the survival of dissociated DRG neurons in response to the neurotrophins. Dissociated DRG neurons from E8 chick were planted onto 35-mm poly-D-lysine-coated plates, and the number of surviving neurons were counted after 1-day treatment with the COS cell supernatant (diluted 6:5 by medium). *Xiphophorus* NGF, NT-7, and NT-7(D15) were able to support survival of the neurons (50-60%) while less than 20% of the neurons survived in response to NT-6, NT-6*, NT-6(D22), or NT-6*(D22), which was similar to that of mock-transfected cells. NT-6* represented NT-6 with pre-pro region of NGF. The error bars represented SEM, n = 6.

Figure 8 shows phosphorylation of chick Trk receptors by the neurotrophins

(A) Chick TrkA was transiently transfected into 293 fibroblasts and assayed for phosphorylation by the COS cell supernatant (undiluted) that contained the

09157984:002200

various fish neurotrophins. Similar observation was obtained using 6:5 diluted COS cell supernatant. The faster migrating band (about 96 kDa) represented constitutively phosphorylated precursor (Ibanez et al., 1993), and its signal could serve to equalise the amount of sample on each lane. All the fish neurotrophins examined, except NT-6, could weakly phosphorylate TrkA, but the extent of phosphorylation was considerably lower than that of *Xiphophorus* NGF. Similarly, NT-6(D22), but not NT-6, that contained NGF pre-pro region could induce weak TrkA phosphorylation (data not shown).

(B) Chick fibroblasts that were stably transfected with chick TrkB were used to test the ability of the neurotrophins to phosphorylate TrkB. Only BDNF (50 ng/ml), which served as the positive control, could phosphorylate the receptor.

(C) Phosphorylation of TrkC by the neurotrophins was tested by chick fibroblasts stably transfected with chick TrkC. All the fish neurotrophins were unable to phosphorylate the receptor, except NT-3 (50 ng/ml) which acted as the positive control (since only one-third of the positive control was loaded, the lower two bands that were present in the other samples were not visible).

Figure 9 shows neurite outgrowth of DRG in response to Fc-tagged neurotrophins. COS cell supernatant that contained equal amounts of the Fc-tagged NGF (B) or NT-6(D22), as determined by ELISA, was added to E8 chick DRG. Only NGF-Fc promoted the neurite outgrowth, while the activity of NT-6(D22)-Fc was similar to mock-transfected COS cell supernatant (A). The

activity of NT-6-Fc was also similar to the mock (data not shown).

Magnification: x60.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to nucleic acid sequences encoding neurotrophin 7 (NT-7) as well as NT-7 protein, peptide fragments and derivatives produced using these nucleic acid sequences. In addition the invention relates to pharmaceutical compositions and therapeutic uses of NT-7.

The invention permits a comparison of the nucleic acid sequences of NT-7 and other neurotrophins.

MATERIALS AND METHODS

1 MOLECULAR CLONING OF XIPHOPHORUS NGF, NT-6, CARP NGF AND NT-7

In an attempt to clone the carp NT-6, two exact oligonucleotides representing the amino acid sequence YSVCDs (GTACTCTGTGTGTGACAG) and INAACV(CACACATGCAGCGTTGA), which corresponded to two conserved regions of NT-6, were designed (Figure 1). Carp genomic DNA (0.6 ug) was used in the polymerase chain reaction (PCR) as template. One-tenth of the reaction was further amplified by the same set of primers in a second PCR. The fragment was then gel purified and the ends were blunted by Klenow (Amersham, UK) before being ligated to *Sma*I-cut pBluescript (Stratagene, CA). After transformation into XL-1 blue, the plasmid was purified and double-

0157984.092268

stranded DNA sequencing was performed (Sanger et al., 1977). The resulting fragment was designated as NT-7. Rapid amplification of cDNA ends (RACE) was employed in order to clone the full-length NT-7 from carp skin RNA. Methods were the same as stated in the protocol (Gibco, NY). The 5'- and 3'-RACE revealed the sequence of part of the pre-pro region and the 3'-untranslated region. To clone the entire mature region, two primers (AAAT-GATACGGGGAGCC and AAGGGGCGGAGTCTCAG) located at the pre-pro and 3'-untranslated regions, respectively, were used to amplify NT-7 from 1.3 ug of carp genomic DNA using Vent polymerase (New England Biolab, MA). The resulting fragment of 553 bp was subcloned into pBluescript by blunt-end ligation as mentioned above. The partial sequence of carp NGF was amplified by PCR from 0.3 carp genomic DNA by a pair of degenerate primers that corresponded to the conserved regions FYETTC and ACVCV. To clone the full-length *Xiphophorus* NGF and NT-6, two pairs of primers (CTTAGATCGTGTGCCCATG and GGGT-GAGTCTTCAATGCTG for NGF; ATAACGTGGACGT-GTGCCC and CAAGAGCGGTCCACACCTC for NT-6) were designed and PCR was performed using 1.8 ug *Xiphophorus* genomic DNA as template. The resulting products were subcloned into the expression vector pMT21. The cDNA sequence for carp NT-7 has been submitted to Genbank, with the Accession Number of 094949.

2 SOUTHERN BLOT ANALYSIS

Genomic DNA was prepared from 3 g of carp or *Xiphophorus* tissues as previously described (Ausubel et al., 1992). Genomic DNA (50 ug) was digested

with 1500 units of *Hind*III for 6 hours, after which it was further digested by 980 units of the enzyme for 16 hours. Digested genomic DNA (16 ug) was loaded to each lane on 1% agarose gel. After being transferred to nylon membrane, it was hybridised at 50 °C in sodium phosphate buffer containing 25% formamide.

3 RNA EXTRACTION, NORTHERN ANALYSIS, AND RT-PCR

Selected tissues were dissected from adult carp and immediately frozen in liquid nitrogen. Total RNA was extracted from homogenized tissues by lithium chloride precipitation or guanidium thiocyanate extraction as described previously (Ip *et al.*, 1995). Total RNA (15 ug) was electrophoresed on a 1% agarose-formaldehyde gel, transferred onto a nylon membrane (MSI, MA), and cross-linked by UV irradiation (Stratalinker, Stratagene, CA). A 340-bp fragment corresponding to the partial sequence of NT-7 was used as the probe for Northern analysis. The DNA fragment was gel purified by Qiaex (Qiagen, Germany) and labelled by random priming (Megaprime labelling kit, Amersham, UK). RNA blots were hybridised at 65 °C with radiolabelled probes in 0.5 M sodium phosphate buffer (pH 7), 1% bovine serum albumin, 7% SDS, 1 mM EDTA, and 20 µg/ml sonicated salmon sperm DNA. Filters were washed at 65 °C with 2x SSX, 0.1% SDS, and exposed to X-ray film (XAR-5, Kodak) with intensifying screens (Model SQZ-, C.B.S. Scientific CO., Inc.) at -80 °C.

For RT-PCR analysis, 2 µg of RNA from various carp tissues was used as template in the reverse transcription that utilised Superscript RT (Gibco, NY). The RNA was pretreated with 1 unit of RNase-free DNase (Promega, WI) for 30

minutes at 37 ° C. For the control, no RT was added and was substituted by DEPC-H₂O. One tenth of the reaction was amplified by two primers flanking the insertion (Figure 1). The resulting product was analysed in agarose gel and subjected to Southern blotting, using the same fragment used in the Northern blot analysis as probe.

4 CONSTRUCTION OF VARIOUS NEUROTROPHINS

A fusion protein that contained the pre-pro region of *Xiphophorus* NGF and mature region of NT-7 was constructed in order to test the activity of NT-7. The pre-pro region was amplified from the expression plasmid *Xiphophorus* NGF in pMT21 by sense primer located upstream of the *Xho*I cloning site of pMT21 and anti-sense primer that contained sequence at the end of the NGF pre-pro region plus 18 nucleotides from the beginning of the NT-7 mature region. The complementary sense primer and the antisense primer downstream of the *Not*I site of pBluescript were used to amplify the mature region of NT-7 (being subcloned into pBluescript). In a second PCR, the two fragments of DNA would anneal at the corresponding position because of the complementarity of the opposite ends, and the resulting NGF pre-pro/NT-7 chimera was amplified by the sense and antisense primers of pMT21 and pBluescript, respectively. The same approach was used to exchange the pre-pro region of NT-6.

To construct NT-7(D15) in which the 15-amino-acid insertion was deleted, a pair of complementary primers was designed which contained sequence immediately flanking the insertion. NT-7 (already fused with the NGF pre-pro region) encoded in pMT21 and pBluescript was used as template to produce the N- and C-

terminal fragments, respectively. Because the two internal primers bypassed the insertion sequence, both the N- and C-terminal fragments did not contain the 15-amino-acid insertion. Using the two fragments as template in a second PCR (which involved sense and antisense primers of the two vectors) would generate NT-7(D15). A similar approach was employed to construct NT-6 lacking the 22-amino-acid insert. Fc-tagged NGF, NT-6, and NT-6(D22) were constructed by fusing the human Fe sequence at the C-termini of the neurotrophins as previously described (Yang et al., 1997). All the different neurotrophin DNAs were subcloned in the expression vector pMT21 and transformed into DN10B.

5 EXPRESSION OF VARIOUS NEUROTROPHINS AND ASSAY FOR BIOLOGICAL ACTIVITIES

All the expression constructs were transfected into COS-5 cells using the diethylaminoethanol (DEAE)-dextran-chloroquine method as previously described (Lai et al., 1996), except that 5 µg of plasmid was used in each transfection, and the cells were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). Three days after transfection, the COS cell supernatant was collected and assayed for stimulation of neurite outgrowth from E8 chick DRG explants as described previously (Lindsay et al., 1985). The COS cell supernatant used in the assay was diluted 1:5 with DMEM + 10% FBS. The DRG were fixed and stained after 1 day treatment by anti-neurofilament 160-kDa antibody (Clone NN18, Sigma, MO) as previously described (Ip et al., 1991). Similarly, the neurite-outgrowth activities of the Fc-tagged neurotrophins were determined except the COS cell supernatant that contained NGF-Fe was diluted 1:2.5 and the amount of NT-6 and NT-6(D22) was correspondingly

adjusted by mock-transfected COS cell supernatant. The relative amount of the Fc-tagged neurotrophins in the COS cell supernatant was determined by ELISA as previously described (Ausubel *et al.*, 1992), using anti-human Fe antibody (Amersham, UK). Based on the absorbance of the COS cell supernatant, the amounts of protein added to the cultures were equalised (equivalent to OD of 0.290 ± 0.01 at 1:10 dilution, $n = 3$, \pm SEM).

To test whether the various neurotrophins could promote the survival of dissociated DRG neurons, the neurons were dissociated as previously described (Lindsay *et al.*, 1985) and $3-4 \times 10^4$ cells (in DMEM + 10% FBS) were plated onto 35-mm plate coated with 100 ng/ml poly-o-lysine, COS cell supernatant (1.2 ml) was added to each plate in a final volume of 2.2 ml (ie, the ratio of COS supernatant to medium was 6:5). The number of surviving neurons were counted after 20 hours.

6 PHOSPHORYLATION ASSAY OF TRK RECEPTORS IN FIBROBLASTS

To test TrkA phosphorylation induced by the neurotrophins, 293 cells were transiently transfected by chick TrkA (Beckstrom *et al.*, 1996) encoded in the expression vector pCDM8, and 2×10^6 cells were plated onto a 100-mm plate. Twenty-four hours later, the cells were transfected with 9 μ g DNA in 8 ml Opti-minimal essential medium (Opti-MEM, Gibco, NY) without penicillin/streptomycin but containing 40 μ g lipofectamine (2 mg/ml, Gibco, NY). The cells were incubated with the liposome-DNA mix for 5 hours at 37 ° C before replaced by DMEM + 10% FBS. The cells were refed at 20-24 hours after the start of transfection. Three days later, $2-3 \times 10^6$ cells were plated onto each 100-mm

plate for phosphorylation assay. After 24 hours, the cells were starved in serum-free defined medium for 1 hour and then 2.5 ml of the COS cell supernatant (undiluted) was added to the cells and they were incubated for 5 minutes at 37 ° C. The cells were lysed by RIPA buffer and assayed for Trk receptor phosphorylation as previously described (Lai *et al.*, 1996). Similar experiment was performed using 6:5 diluted COS cell supernatant. This served to show that NT-6(D22) and NGF/NT-6(D22) could still induce the weak TrkA phosphorylation under the same dilution utilised in the DRG survival assay. To assay TrkB and TrkC phosphorylation, 2 X 10⁶ chick fibroblasts stably transfected with full-length chick TrkB or TrkC were plated and the same procedure for TrkA phosphorylation was followed.

The invention will now be described by way of example only, with reference to the following Examples:

EXAMPLE 1

MOLECULAR CLONING OF CARP NT-7 AND NGF

A DNA fragment of 340 bp was amplified from carp genomic DNA using primers corresponding to two conserved regions of NT-6 (Figure 1A). Subsequent cloning and DNA sequence analysis suggested the fragment might represent partial sequence of a novel neurotrophin. Northern blot analysis revealed its relatively strong expression in skin (see below). Therefore, in order to obtain the full-length sequence, 5'- and 3'- RACE (rapid amplification of cDNA ends) was performed using carp skin cDNA as template. The full-length clone which

contained the putative translation start codon ATG and the signal peptide was not generated by the 5'-RACE. However, DNA sequence of the entire mature region could be obtained from the resulting clones. Subsequently, PCR using primers designed from sequence at the pre-pro and the 3'-untranslated region was performed to amplify the entire mature region.

DNA sequence analysis revealed that the pre-pro region was terminated at the two basic amino acids, arginine, followed by a mature region of 133 amino acids (Figure 1A). The R-X-K/R-R sequence was conserved in all neurotrophins and represented the proteolytic cleavage site, at which the mature protein was cleaved from its larger precursor (Hosaka *et al.*, 1991). The presence of all 6 conserved cysteine residues together with the nearby conserved regions in the mature protein suggested that it represented a novel neurotrophin molecule. Amino acid alignment of this novel neurotrophin, designated NT-7, with that of *Xiphophorus* NGF and NT-6 revealed 66% identity (Figure 2A). Moreover, alignment with carp BDNF, chick NT-3, and *Xenopus* NT-4 suggested even more distant relationships (Figure 2A). However, NT-7 lacked some amino acid residues which were conserved in all NGF molecules identified so far (Figure 2B).

Because of its structural similarity to NGF, it was possible that NT-7 merely represented the carp homologue of NGF. However, Southern blot analysis of carp genomic DNA revealed that different DNA fragments hybridised with *Xiphophorus* NGF and carp NT-7 (data not shown), suggesting that NGF and NT-7 represented different genes. To clone the carp NGF homologue, PCR was performed using several pairs of degenerate primers that corresponded to conserved regions near the cysteine residues. As a result, a 177-bp fragment

was amplified from carp genomic DNA by one of the pairs of primers (Figure 1B). Analysis of the deduced amino acid sequence indicated its close resemblance to NGF; it shared amino acid identity to the corresponding region of *Xiphophorus* NGF, carp NT-7, *Xiphophorus* NT-6, chick NT-3, carp BDNF, and *Xenopus* NT-4, respectively (Figures 2A and 2B). In addition, it lacked those amino acid residues that were highly conserved in either BDNF, NT-3, or NT-4 of different species (Hallbook *et al.*, 1991). These finding strongly suggested that this clone represented the partial sequence of carp NGF.

EXAMPLE 2

SOUTHERN BLOT ANALYSIS OF XIPHOPHORUS GENOMIC DNA

To examine whether NGF, NT-6, and NT-7 represent three different genes that coexist in one genome, Southern blot analysis of *Xiphophorus* genomic DNA, digested by *Hind*III, was performed and hybridised with *Xiphophorus* NF, NT-6, or carp NT-7 cDNAs under low stringency conditions. It was found that different patterns were obtained by hybridisation with the three neurotrophin cDNAs. The DNA fragments that hybridised with NGF were ~8 and ~3 kb, while a single fragment of ~8 and ~2 kb hybridised with NT-6 and NT-7, respectively (Figure 3). This suggested that NGF, NT-6, and NT-7 did represented three different genes.

EXAMPLE 3

SPATIAL EXPRESSION OF NT-7 IN ADULT CARP

The spatial expression of NT-7 in adult carp was studied by Northern blot analysis. A single transcript of about 1.1 kb was detected in skin and heart, though weak expression was also found in brain and intestine (Figure 4A). This was in contrast with that of NT-6, where expression in adult fish was predominantly found in brain, gill, liver, and eye, but not skin (Gotz *et al.*, 1994).

Furthermore, the expression of NGF was studied in adult *Xiphophorus* in order to compare its spatial expression with that of NT-7. Northern blot analysis revealed dominant expression of a single transcript of ~3.6 kb in eye and gill, though weak expression could be detected in skin (Figure 4B).

EXAMPLE 4

PRESENCE OF THE 15-AMINO-ACID INSERTION IN THE NT-7 TRANSCRIPT AS DETERMINED BY RT-PCR

One of the interesting features of NT-7 was the insertion of 15 amino acids between the second and third cysteine residues, a feature not found in any other known neurotrophins (including *Xiphophorus* NT-6 which contained an insertion of 22 amino acids at the corresponding position). The insertion contained only 4 glycine and 2 basic amino acid residues compared to the 8 glycine and 6 basic amino acid residues in *Xiphophorus* NT-6 that corresponded to the heparin-binding domain. In order to rule out the possibility of the insertion being an intron, RT-PCR was performed using a pair of primers flanking the insertion. All the tissues that were shown to express NT-7 in the Northern blot produced a single band which corresponded to the size having the insertion. Moreover, the

band was absent when RT was performed using the same RNA samples but without reverse transcriptase (Figure 5). Thus, the resulting product which contained the insertion was not originated from contaminating genomic DNA, and there was no detectable alternative form of the NT-7 transcript that lacked the insertion.

EXAMPLE 5

CONSTRUCTION OF NT-7 AND TRUNCATED NT-7 THAT LACKED THE INSERTION

Although the entire pre-pro region of NT-7 was not obtained, its biological activity could still be determined upon fusion of its mature region with the pre-pro portion of *Xiphophorus* NGF in order to express the protein. Moreover, it was reported that NT-6 might bind to cell surface through the heparin-binding domain, which would hinder its release into the conditioned medium after transfection. With the assumption that the 22 amino acids that corresponded to the heparin-binding domain are not essential in its biological activity, a truncated form of NT-6, named NT-6(D22), was constructed in which the 22 amino acid insertion was deleted in order to assay its neurotrophin activity in conditioned medium. Since NT-7 was expressed using the *Xiphophorus* NGF pre-pro region, two additional constructs of NT-6 and NT-6(D22), with pre-pro exchange, were made. Furthermore, the 15 amino acid insertion in NT-7 might lead to its binding to extracellular matrix, just like NT-6. Accordingly, a truncated form of NT-7 that lacked the 15-amino-acid insertion, NT-7(D15), was also constructed.

EXAMPLE 6

BIOLOGICAL ACTIVITIES OF NT-7

All the expression constructs were transiently transfected into COS-5 cells and conditioned medium was collected after 3 days. Neurite outgrowth assay of chick embryonic dorsal root ganglia (DRG) was employed to test the biological activities of the various neurotrophins. Addition of either *Xiphophorus* NGF or NT-7 resulted in robust neurite outgrowth from E8 DRG (Figure 6). Moreover, NT-7(D15) also showed comparable activity, suggesting that NT-7 was still active without the 15-amino-acid insertion. In contrast, the effect of either NT-6 or NT-6(D22) was similar to that obtained from conditioned medium of mock-transfected cells. Similar results were observed for the two NT-6 constructs with pre-pro exchange (data not shown). The neurotrophic activity of NT-7 was further investigated by the survival assay of dissociated DRG neurons. Consistent with the results of the neurite outgrowth assay, both NT-7 and NT-7(D15) could support the survival of E8 chick DRG neurons (Figure 7). On the other hand, NT-6 and NT-6(D22) failed to promote significant neuronal survival, irrespective of the pre-pro region. Thus, the neurotrophic activity of NT-7 was demonstrated by its ability to stimulate neurite outgrowth and survival of DRG neurons, in a manner similar to that induced by *Xiphophorus* NGF.

EXAMPLE 7

PHOSPHORYLATION OF TRK RECEPTORS BY NT-7

To elucidate its mechanism of action, the interaction between NT-7 and the various Trk receptors was studied by phosphorylation of different Trk receptors ectopically expression in fibroblasts. Because of its structural similarity to NGF, it would be expected that NT-7 showed receptor specificity to TrkA. Indeed, compared with the conditioned medium of mock-transfected COS cells, NT-7, NT-7(D15), and NT-6(D22) could weakly phosphorylate TrkA but not TrkB or TrkC (Figure 8). It should be noted that despite the relatively weak level of TrkA phosphorylation, it was consistently observed in triplicate experiments. The extent of TrkA phosphorylation elicited by NT-7, NT-7(D15), and NT-6(D22) was considerably lower than that obtained by *Xiphophorus* NGF, NT-6(D22) failed to promote neurite outgrowth and survival of DRG, yet its induction of TrkA phosphorylation was similar to NT-7 and NT-7(D15). On the other hand, with the presence of the 22-amino-acid insertion, NT-6 was unable to stimulate any detectable level of TrkA phosphorylation, probably because of its binding to the cell surface or extracellular matrix, which subsequently hindered its release to the conditioned medium. Similarly, NT-6(D22) with NGF pre-pro region could induce weak TrkA phosphorylation (data not shown).

EXAMPLE 8

CONSTRUCTION OF Fc-TAGGED NGF AND NT-6 AND ASSAY FOR NEURITE OUTGROWTH ACTIVITY

Since NT-6 had been demonstrated to promote the survival of chick DRG neurons (Gotz *et al.*, 1994), the negative activity of NT-6 or NT-6(D22) in our

study might be explained by lower expression and/or potency of the neurotrophin compared with NGF. To address this question, constructs of *Xiphophorus* NGF, NT-6, and NT-6(D22) were tagged with the Fc region of human IgG. The relative amount of each neurotrophin in the conditioned medium was then determined by ELISA (see Experimental Methods), and their ability to stimulate neurite outgrowth of chick DRG was assayed after equalising the amount of each neurotrophin.

It was found that only NGF-Fc could stimulate the neurite outgrowth of DRG, while the activity of NT-6(D22)-Fc as well as NT-6-Fc (data not shown) was similar to that of conditioned medium of mock-transfected cells (Figure 9). Therefore, the different response of DRG to the two neurotrophins in our study was likely due to the lower potency of NT-6 in promoting neurite outgrowth. Indeed, the EC₅₀ of purified NT-6 in supporting the survival of chick DRG was quite high (about 100 ng/ml; Gotz *et al.*, 1994). It was therefore possible that the expression level of NT-6 and NT-6(D22) in our study was not high enough to reveal its activity on DRG neurons.

DISCUSSION

NT-6 was originally cloned from the aquarium fish *Xiphophorus maculatus* (Gotz *et al.*, 1994), but so far no homologue in any other vertebrate was found. With the assumption that NT-6 was highly homologous among different types of fish, particularly at the conserved regions around the cysteine residues, PCR was performed using a pair of primers at two conserved regions in order to clone the

carp NT-6 homologue. It was therefore surprising that the resulting fragment, designated NT-7, only shared 66% amino acid identity to *Xiphophorus* NT-6. Apart from the relatively low percentage of homology, there was also considerable differences between the primary structure of the two neurotrophins. For example, the lack of an amino acid between Asn²³ and Lys²⁴, which was characteristic to NT-6 but not any other known neurotrophins, was found in NT-7 (Figure 2A). Moreover, the insertion present in NT-7 was considerably different from that of NT-6 in terms of the length and number of basic amino acid residues. Southern blot analysis demonstrated that NGF, NT-6, and NT-7 represented three different genes in the *Xiphophorus* genome. The partial sequence of carp NGF cloned in our study indicated that NGF and NT-7 were indeed two different genes. Since the homology between NGF and NT-7 is very similar to that between NT-7 and NT-6 (about 66% in both cases), it supports our claim that NT-7 represents a different gene from NT-6, rather than the carp NT-6 homologue. In addition, the spatial expression of NT-7 in adult tissues was quite different from that of *Xiphophorus* NGF and NT-6. In particular, high level of expression of NT-6 was reported in adult brain, eye, and gill, while NT-7 expression in the brain was low, and was even undetectable in eye and gill. Taken together, despite the relatively high evolutionary rate of neurotrophin in lower vertebrates (Gotz *et al.*, 1992), NT-7 represents a novel member of the neurotrophin family.

In the present study, we have demonstrated the ability of NT-7 to stimulate neurite outgrowth and survival of E8 chick DRG. Unlike NT-7 and *Xiphophorus* NGF, NT-6 was unable to induce positive response from DRG in either assay. Although it has previously been suggested that the pre-pro region can affect the

processing of mature neurotrophin (Ip *et al.*, 1992), the pre-pro exchange with that of *Xiphophorus* NGF could not enable NT-6 to induce neurite outgrowth from DRG. It was possible that NT-6 secretion into the conditioned medium was hindered by its binding to cell surface or extracellular matrix, as suggested by Gotz *et al* (1994). However, NT-6(D22), which was expected to be released to the medium because of the absence of the heparin-binding domain, also could not activate the DRG in the neurite outgrowth and survival assay. Our assays using Fc-tagged NT-6(D22) suggested that NT-6 was less potent than NGF in stimulating neurite outgrowth of chick DRG. This finding is indeed consistent with the results obtained in two separate studies (Gotz *et al.*, 1992, 1994), which suggested that NT-6 was much less potent than *Xiphophorus* NGF in promoting the survival of DRG: the concentration of *Xiphophorus* NGF causing half-maximal activity was 6 compared to 100 ng/ml of NT-6. It was possible that in our experiments, the concentration of the neurotrophin in COS cell supernatant was below the half-maximal value of NT-6 but not NGF, thus allowing for detectable response to NGF but not NT-6 in the DRG. Nonetheless, NT-6(D22) did exhibit the ability to induce weak TrkA phosphorylation.

Neurotrophins mediate their actions via phosphorylation of the Trk receptors. In our studies, the receptor specificity of NT-7 was determined by phosphorylation of chick Trks ectopically expressed in fibroblasts. As expected from the structural similarity to NGF, NT-7, NT-7(D15), and NT-6(D22) specifically phosphorylated TrkA. However, the phosphorylation was considerably weaker than that induced by *Xiphophorus* NGF. The weaker phosphorylation of TrkA by NT-6(D22) or NGF/NT-6(D22) was consistent with our hypothesis that NT-6 was less potent than *Xiphophorus* NGF in activating DRG neurons. However, NT-7

and NT-7(D15), despite their ability to activate DRG in both neurite outgrowth and survival assay, could only phosphorylate TrkA weakly. Indeed, the extent of TrkA phosphorylation was similar to that induced by NT-6(D22), which did not show any detectable activity on DRG in our studies. Both NT-7 and NT-7(D15) could not phosphorylate TrkB and TrkC, suggesting that the action on DRG was not mediated by these two Trk receptors. It remains possible that NT-7, but not NT-6, can activate a unique signalling pathway that mediates the response of DRG despite the modest activation of TrkA.

One important feature of NT-7 is the insertion of 15 amino acids at the position corresponding to the insertion of *Xiphophorus* NT-6. The insertion lacks the GT-AG sequence that is conserved in the intron/exon boundary. This, together with the result of RT-PCR, suggested that the insertion did not represent an intron. Since the activity of NT-7(D15) was as potent as NT-7 in both the DRG assay and the phosphorylation assay, the 15-amino-acid insertion was not indispensable in its biological activity. Its presence in the NT-7 molecule might be accessory to its neurotrophic function, such as binding to extracellular matrix which helped to localise the factor in the target area. If that is the case, it will be interesting to examine whether NT-7, like NT-6, binds to heparan sulfate or other types of molecules present in the extracellular matrix.

The cloning of this novel neurotrophin from carp shed new light on the diversity of neurotrophins in lower vertebrates. Considerable differences among NT-7, NGF, and NT-6 were observed in terms of primary structure and spatial expression. This, together with the Southern analysis of *Xiphophorus* genomic DNA and the low homology between NT-6 and NT-7 which is comparable with that of NGF, provide evidence that NT-7 is a novel neurotrophin.

WHAT IS CLAIMED IS:

- 1 An essentially purified neurotrophin, NT-7 having neurotrophic activity and an amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7.

2

AAGGCCAACGACTTCTTGCATCGCGGCGAGTACTCTGTGTGTGACAGCGAAGA
GCACTGGGTTGGCAACCTGACCCAAGCCACAGACTTACGGGGCAATGAAGTCA
CGGTGCTGCCACATGTTTCGCATCAACAACGTGGTGAAGAAGCAGATGTTCTAC
GAGACCACGTGCCGTGTGTCTGAAGCCCATCGGGGCCCCAAGCCGGGTCAAG
GAGTCAGCGGCGTTAAAGCAGGAACCTCTAGCTGTCTGGGATCGACAACGAG
CACTGGAACCTCTATTGCACCAACGTGCACACCTTTGTGCGGGCGTTAACGTCC
TACAAAAACCAGATTGCCTGGAGGTTTATCCGAATCAACGCCGCTTGCGTGTG
CGTCTCAGCCGCAACTCATGGAGGCAT

said nucleic sequence including degenerate versions of the sequence and
including nucleic acid sequences that hybridise under stringent conditions to said
nucleic acid sequences and encode NT-7.

3 A composition comprising an essentially purified neurotrophin, NT-7

having neurotrophic activity and an amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7.

4 An essentially purified neurotrophin NT-7 having neurotrophic activity and an
amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7 in the
treatment of acute and/or chronic neuronal injury or degenerative states for a
specific subclass of neurons.

5 The use of an essentially purified neurotrophin NT-7 having neurotrophic
activity and an amino acid sequence as follows:

Lys Ala Asn Asp Phe Leu His Arg Gly Glu Tyr Ser Val Cys Asp Ser Glu Glu His Trp
 Val Gly Asn Leu Thr Gln Ala Thr Asp Leu Arg Gly Asn Glu Val Thr Val Leu Pro His
 Val Arg Ile Asn Asn Val Val Lys Lys Gln Met Phe Tyr Glu Thr Thr Cys Arg Val Ser
 Lys Pro Ile Gly Ala Pro Lys Pro Gly Gln Gly Val Ser Gly Val Lys Ala Gly Thr Ser Ser
 Cys Arg Gly Ile Asp Asn Glu His Trp Asn Ser Tyr Cys Thr Asn Val His Thr Phe Val
 Arg Ala Leu Thr Ser Tyr Lys Asn Gln Ile Ala Trp Arg Phe Ile Arg Ile Asn Ala Ala
 Cys Val Cys Val Leu Ser Arg Asn Ser Trp Arg His

or functional variants, analogues and functional fragments of NT-7 in the
 identification of additional members of the neurotrophin family.

09157984-092299

ABSTRACT

The present invention relates to a novel neurotrophin, NT-7. The present invention relates to nucleic acid sequences encoding neurotrophin-7, and to the substantially pure protein. The neurotrophin NT-7 was isolated from the fish, *Cyprinus carpio* (carp). NT-7 was found to be primarily expressed in skin, heart, and to a weaker extent in the intestine and brain in the adult fish.

Expression of the recombinant protein enabled the demonstration of its ability to support the survival and neurite outgrowth of embryonic chick dorsal root ganglion neurons. NT-7 can activate the receptor tyrosine kinase, Trks. Activity of NT-7 on neurons is likely to be mediated by the binding and phosphorylation of the TrkA receptor.

03157904-092298

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to Provisional and PCT International Applications)

ATTORNEY'S DOCKET NUMBER

007198- 353

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Cloning of a Novel Neurotrophin NT-7 from Carp.

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Number _____

on _____

and was amended

on _____ (if applicable).

☐ was filed as PCT international application

Number _____

on _____

and was amended under PCT Article 19

on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

(Application Number) _____

(Filing Date) _____

(Application Number) _____

(Filing Date) _____

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED) (Includes Reference to Provisional and PCT International Applications)				ATTORNEY'S DOCKET NO 007198- <u>393</u>	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations §1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS				STATUS (check one)	
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)			
<p>I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:</p>					
William L. Mathis Peter H. Smolka Robert S. Swecker Platon N. Mandros Benton S. Duffett, Jr. Joseph R. Magnone Norman H. Stepno Ronald L. Grudziecki Frederick G. Michaud, Jr. Alan E. Kopecki Regis E. Stiner Samuel C. Miller, III	17,337 15,913 19,885 22,124 22,030 24,239 22,716 24,970 26,003 23,813 26,999 27,360	Ralph L. Freeland, Jr. Robert G. Makai George A. Hovanec, Jr. James A. LaBarre E. Joseph Gess R. Danny Huntington Eric H. Wessblatt James W. Peterson Teresa Stanek Rea Robert E. Krebs Robert M. Schulman	16,110 28,531 28,223 28,632 28,510 27,903 30,505 26,057 30,427 25,885 31,196	William C. Rowland T. Gene Dillahunty Anthony W. Shaw Patrick C. Keane Bruce J. Boggs, Jr. William H. Benz Peter K. Skiff Richard J. McGrath Matthew L. Schneider Michael G. Savage Gerald F. Swiss	30,888 25,423 30,104 32,858 32,344 25,952 31,917 29,195 32,814 32,596 30,113
<p>and: _____</p>					
Address all correspondence to:		James A. LaBarre BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404			
Address all telephone calls to:		<u>James A. LaBarre</u> at (703) 836-6620.			
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p>					

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED)
(Includes Reference to Provisional and PCT International Applications)

ATTORNEY'S DOCKET NO.

007198: 353

FULL NAME OF SOLE OR FIRST INVENTOR <u>Kwok On Lai</u>		SIGNATURE <u>[Signature]</u>	DATE <u>13th Aug, 1998</u>
RESIDENCE <u>218 Johnston Road, 10th Floor, Wan Chai, Hong Kong</u>		CITIZENSHIP <u>Hong Kong</u>	
POST OFFICE ADDRESS			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY <u>Nancy Yuk-Yu Ip</u>		SIGNATURE <u>[Signature]</u>	DATE <u>Aug 20, 1998</u>
RESIDENCE <u>7A Repulse Bay Towers, 119A Repulse Bay Road, Hong Kong</u>		CITIZENSHIP <u>Hong Kong</u>	
POST OFFICE ADDRESS			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			